NeuroSense Therapeutics Ltd. (NRSN) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
6.32
↑+34% vs avg
5yr avg: 4.70
30Y Low2.5·High8.6
ROE
↓
-2880.1%
↑-257% vs avg
5yr avg: -806.2%
30Y Low-359%·High-84%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NRSN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NeuroSense Therapeutics Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $20M | $22M | $11M | $14M | $27M | — | — |
| Enterprise Value | $17M | $19M | $8M | $11M | $17M | — | — |
| P/E Ratio → | -1.59 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 6.32 | 8.64 | — | 2.50 | 2.97 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NRSN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
NRSN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -2880.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -2880.1% | -2880.1% | -539.8% | -168.8% | -83.6% | -358.7% | -133.7% |
| ROA | -263.4% | -263.4% | -185.7% | -128.9% | -66.2% | -326.2% | -128.5% |
| ROIC | — | — | — | -987.8% | — | — | — |
| ROCE | -861.0% | -861.0% | -422.7% | -161.2% | -97.2% | -366.3% | -134.5% |
NRSN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $73000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | 0.04 | 0.20 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.28 | — | -0.59 | -1.03 | -1.06 | -0.97 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -31.84 | -31.84 | -21.91 | -903.47 | -4.84 | — | -247.00 |
Net cash position: cash ($3M) exceeds total debt ($73000)
NRSN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NeuroSense Therapeutics Ltd.'s current ratio of 2.21x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.28x to 2.21x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | 2.21 | 0.84 | 4.28 | 19.12 | 6.08 | 24.68 |
| Quick Ratio | 2.21 | 2.21 | 0.84 | 6.41 | 19.41 | 6.08 | 24.68 |
| Cash Ratio | 1.70 | 1.70 | 0.76 | 4.11 | 18.53 | 5.83 | 24.19 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
NRSN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NeuroSense Therapeutics Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $19M | $14M | $12M | $11M | $6M | $5M |
Peer Comparison
Compare NRSN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NRSNYou | $20M | -1.6 | — | — | — | — | -2880.1% | — | — |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACIU | $298M | -3.3 | — | — | 100.0% | -1927.3% | -89.6% | -99.2% | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 ANVS | $62M | -1.6 | — | — | — | — | -0.3% | — | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 CLVT | $2B | -9.3 | 7.2 | 4.9 | 66.0% | 2.9% | -4.0% | 0.6% | 5.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 AMRX | $4B | 62.4 | — | 16.0 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See NRSN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRSN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRSN vs PRTA
Side-by-side business, growth, and profitability comparison vs Prothena Corporation plc.
Start ComparisonNRSN — Frequently Asked Questions
Quick answers to the most common questions about buying NRSN stock.
What is NeuroSense Therapeutics Ltd.'s P/E ratio?
NeuroSense Therapeutics Ltd.'s current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
What is NeuroSense Therapeutics Ltd.'s ROE?
NeuroSense Therapeutics Ltd.'s return on equity (ROE) is -2880.1%. The historical average is -186.2%.
Is NRSN stock overvalued?
Based on historical data, NeuroSense Therapeutics Ltd. is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.